Loading stock data…
OCGN
$1.80+0.07 (+4.05%)
Market ClosedLast close May 1
Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Ocugen, Inc. in the Healthcare sector is trading at $1.80. The stock is currently 34% below its 52-week high of $2.73, remaining 21.6% above its 200-day moving average. Technical signals show neutral RSI of 51 and bearish MACD signal, explaining why OCGN maintains its current momentum and trend strength. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 51) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$1.80
Potential Upside
5%
Whystock Fair Value$1.89
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene thera...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$550.87M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
2.81
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
468.02%
Volume
Today's trading volume
3.76M
Recent News
Ocugen (OCGN) Completes Enrollment for Phase 2/3 Pivotal Trial of OCU410ST Gene Therapy
Ocugen Inc. (NASDAQ:OCGN) is one of the best biotech penny stocks to buy in 2026. On April 1, Ocugen completed dosing ahead of schedule in its Phase 2/3 GARDian3 pivotal clinical trial for OCU410ST, a first-in-class modifier gene therapy for Stargardt disease. The trial reached its enrollment target of 63 participants in less than 9 […]
How The Ocugen (OCGN) Story Is Shifting With Gene Therapy Milestones And Valuation Debate
Ocugen’s latest analyst update keeps the central fair value estimate at US$11.57, while published price targets from different firms span US$10, US$12 and US$22. That spread reflects contrasting views on the company’s gene therapy pipeline, with some analysts focusing on recent OCU410 and OCU400 data and BLA timelines, and others stressing execution, safety and financing risks. Looking ahead, you will see how this mix of steady fair value, widely ranged targets and new clinical milestones is...
Ocugen (OCGN) Valuation Check After Encouraging Phase 2 ArMaDa Results For OCU410
Ocugen (OCGN) has drawn fresh investor attention after releasing full Phase 2 ArMaDa data for OCU410, showing a 46% reduction in macular lesion growth at 12 months and no therapy related serious adverse events. See our latest analysis for Ocugen. Despite the recent ArMaDa update, Ocugen’s 1 day share price return of 5.08% and 7 day return of 13.85% sit against a 21.74% year to date gain and a very large 1 year total shareholder return. This hints that enthusiasm around its gene therapy...
OCGN Gene Therapy Pipeline: Key 2026-27 Catalysts Ahead
Ocugen faces a packed 2026-27 catalyst window with filings, interim data and Phase III readouts across three one-time retinal gene therapies.
Ocugen Stock Outlook: Valuation, Cash Runway and Dilution Risk
Ocugen offers upside from a packed 2026 catalyst calendar, but cash runway limits and dilution risk keep the pre-commercial biotech outlook finely balanced.